KLF4 and breast cancer: The increased methylation level of CpG sites in the KLF4 promoter and decreased expression level of KLF4 in BC tissues lead to the resistance to paclitaxel, which has become the target of 3,3’-diindolylmethane in improving the effectiveness of cancer chemotherapy (224).